/FRLN

FRLN Stock - Freeline Therapeutics Holdings plc

Q: What is the analyst price target for FRLN?

Analyst price target information is not currently available for FRLN.

Q: What is FRLN's market cap?

Market capitalization information is not currently available for FRLN.

Healthcare|Biotechnology|NASDAQ

$6.49+0.15%

+$0.01 (+0.15%) • Feb 16

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $7.14

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for FRLN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.66

52W High$8.74

52W Low$2.11

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-1,739,925	$-2,389,715	$-1,927,881	$-1,546,374	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-98,447,000	$-142,379,000	$-102,449,000	$-63,644,000	$-40,981,000
Net Income	$-88,972,000	$-140,391,000	$-96,322,000	$-53,909,000	$-33,283,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-22.52	$-58.98	$-102.09	$-127.39	$-78.65

Company Overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Visit Website

Earnings History & Surprises

FRLN

Beat Rate

36%

Last 14 quarters

Avg Surprise

-229.1%

EPS vs Estimate

Beats / Misses

5/9

Last 12 quarters

Latest EPS

$-5.22

Q2 2024

EPS Surprise History

Q2 22

-8.5%

$-9.40vs$-8.66

Q3 22

+40.7%

$-4.78vs$-8.06

Q4 22

+53.4%

$-2.99vs$-6.42

Q1 23

-234.5%

$-0.97vs$-0.29

Q2 23

-68.4%

$-5.22vs$-3.10

Q3 23

+94.2%

$-0.21vs$-3.62

Q4 23

+21.7%

$-0.18vs$-0.23

Q2 24

-1907.7%

$-5.22vs$-0.26

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	Apr 2, 2024	$-0.26	$-5.22	-1907.7%	✗ MISS
Q4 2023	Dec 1, 2023	$-0.23	$-0.18	+21.7%	✓ BEAT
Q3 2023	Aug 15, 2023	$-3.62	$-0.21	+94.2%	✓ BEAT
Q2 2023	Apr 4, 2023	$-3.10	$-5.22	-68.4%	✗ MISS
Q1 2023	Mar 30, 2023	$-0.29	$-0.97	-234.5%	✗ MISS
Q4 2022	Nov 15, 2022	$-6.42	$-2.99	+53.4%	✓ BEAT
Q3 2022	Aug 9, 2022	$-8.06	$-4.78	+40.7%	✓ BEAT
Q2 2022	May 10, 2022	$-8.66	$-9.40	-8.5%	✗ MISS
Q1 2022	Mar 31, 2022	$-10.75	$-14.48	-34.7%	✗ MISS
Q4 2021	Nov 9, 2021	$-1.01	$-0.86	+14.9%	✓ BEAT
Q3 2021	Aug 16, 2021	$-0.97	$-1.12	-15.5%	✗ MISS
Q2 2021	May 17, 2021	$-0.78	$-0.98	-25.6%	✗ MISS
Q1 2021	Mar 31, 2021	$-0.70	$-0.88	-25.7%	✗ MISS
Q4 2020	Oct 29, 2020	$-0.89	$-10.78	-1111.8%	✗ MISS
Q3 2020	Aug 10, 2020	—	$-39.47	—	—
Q2 2020	Jun 30, 2020	—	$-7.24	—	—
Q2 2019	Jun 30, 2019	—	$-0.63	—	—
Q1 2019	Mar 31, 2019	—	$-0.63	—	—
Q2 2018	Jun 30, 2018	—	$-0.39	—	—
Q1 2018	Mar 31, 2018	—	$-0.39	—	—

Frequently Asked Questions about FRLN

What is FRLN's current stock price?

Freeline Therapeutics Holdings plc (FRLN) is currently trading at $6.49 per share. The stock has moved +0.15% today.

What is the analyst price target for FRLN?

No analyst price targets are currently available for this stock.

What sector is Freeline Therapeutics Holdings plc in?

Freeline Therapeutics Holdings plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is FRLN's market cap?

Freeline Therapeutics Holdings plc has a market capitalization of $0.03 billion, making it a small-cap company.

Does FRLN pay dividends?

No, Freeline Therapeutics Holdings plc does not currently pay a dividend to shareholders.